Introduction

▼
Nonsteroidal anti-infl ammatory drugs (NSAIDs) have been recognized as important class of therapeutic agents for the alleviation of pain and infl ammation associated with a number of pathological conditions. However, long term use of NSAIDs has been associated with several side eff ects such as gastrointestinal mucosal damage, bleeding, intolerance and renal toxicity [ 1 -4 ] . Thus, there is an urgent need for new targets that are required for the design and development of novel anti-infl ammatory agents as an alternative to NSAIDs. Extensive research has been directed towards improving their pharmacological profi le that led to the discovery of multiple isoforms of cyclooxygenase (COX) that are diff erently regulated [ 5 , 6 ] . The discovery of the inducible isoform of cyclooxygenase enzyme (COX-2) spurred the search for anti-infl ammatory agents devoid of the undesirable eff ects associated with classical NSAIDs. Recently, a novel class of selective COX-2 inhibitors has been discovered. Among this class, celecoxib was shown to be a potent and gastrointestinal (GI) safe anti-infl ammatory analgesic agent. It is considered a typical model of pyrazole containing, diaryl-heterocyclic template that is known to selectively inhibit COX-2 anti-infl ammatory activity in model of acute infl ammation such as carrageenan-induced rat edema paw while compound 4d showed considerable activity in model of chronic infl ammation such as adjuvant-induced arthritis along with minimum ulcerogenic index and were compared with diclofenac (13.5 mg/kg b.w.) as a standard drug. Additionally, the synthesized compounds were evaluated for their in vitro antioxidant activity. Compound 4k was found to be the most active antioxidant in the series compared with standard vitamin C.
All research chemicals were purchased from Sigma-Aldrich (St. Louis, Missouri, USA) or Lancaster Co. (Ward Hill, MA, USA) and used as such for the reactions. Solvents except laboratory reagent grade were dried and purifi ed according to the literature when necessary. Reactions were monitored by thin-layer chromatography (TLC) on pre-coated silica gel plates from E. Merck and Co. (Darmstadt, Germany). Melting points of synthesized compounds were determined in Thermonik (Mumbai, India) melting point apparatus and are uncorrected, UV spectra were recorded on Thermospectronic (Rochester, NY, USA) and IR spectra were recorded on Thermo Nicolet IR200 FT-IR Spectrometer (Madison, WI, USA) by using KBr pellets. The 1 HNMR were recorded on Bruker AVANCE 300 (Bruker, Rheinstetten/Karlsruhe, Germany) using DMSO-d 6 as solvent. Chemical shifts are reported in δ ppm units with respect to TMS as internal standard. The purity of compounds was examined by TLC on silica gel plate using chloroform and methanol (10:1) as mobile phase and iodine vapours as visualizing agent. The anti-infl ammatory activity was carried out using digital plethysmometer (Ugo-Basile, Italy). A series of 3-[3-(substituted phenyl)-1-phenyl-1H-pyrazol-5-yl]-2H-chromen-2-one ( 4a-k ) was synthesized by earlier reported method [ 23 ] . The physico-chemical and spectral data of synthesized compounds 4a-k is summarized in • ▶ Table 1 , 2 respectively.
Pharmacological Evaluation
▼
Albino mice of either sex weighing 20-25 g were used for acute toxicity studies and analgesic activity. Healthy male albino adult rats weighing 150-230 g were used for various pharmacological screenings. Animals were procured from Department of Pharmacology, RVS College of Pharmaceutical Sciences, Sulur, Tamilnadu, India, (1012/C/06/CPCSEA) and housed individually in polypropylene cages, maintained under standard conditions of alternating 12 h light and dark cycles at a constant temperature (25 ± 2 °C and 35-60 % relative humidity). Animals were fed with standard rat pellet diet, (Hindustan Lever Ltd., Mumbai, India) and water ad libitum.
Acute toxicity [ 24 ]
The acute toxicity test was carried out according to the Organization for Economic Co-operation and Development (OECD) guidelines to establish the eff ective dose of test compounds after obtaining ethical clearance from Animal Ethics Committee of RVS College of Pharmaceutical Sciences, Sulur (India). Albino mice of either sex weighing between 20 and 25 g were grouped into 12 groups of 6 animals each, starved for 24 h with water ad libitum prior to test. On the day of the experiment animals were administered with diff erent compounds to diff erent groups in an increasing dose of 10, 20, 100, 200, 1 000 and 2 000 mg/kg body weight orally. The animals were then observed continuously for 3 h for general behavioral, neurological, autonomic profi les and then every 30 min for next 3 h and fi nally for next 24 h or till death.
Acute anti-infl ammatory activity
In vivo acute anti-infl ammatory activity was evaluated using carrageenan-induced rat paw edema assay model of infl ammation by adopting the method of Winter et al. [ 25 ] for the compounds listed in • ▶ Table 3 . Male albino rats (170-220 g) were fasted with free access to water at least 12 h prior to experiments and were divided randomly into 13 groups of 6 each. Control group received 1 ml of 0.5 % sodium carboxymethyl cellulose (sodium CMC), standard group received 13.5 mg/kg of diclofenac and test groups received 200 mg/kg of synthesized compounds ( 4a-k ). The rats were dosed orally, 1 h later; a subplantar injection of 0.05 ml of 1 % solution of carrageenan in sterile distilled water was administered to the left hind footpad of each animal. The paw edema volume was measured with a digital plethysmometer at 0, 1, 2, 3, 4, 5 h after carrageenan injection. Paw edema volume was compared with vehicle control group and percent reduction was calculated as 1-(edema volume in the drug treated group/edema volume in the control group) × 100.
Chronic anti-infl ammatory activity
In vivo chronic anti-infl ammatory activity was assessed using adjuvant-induced arthritis assay model of infl ammation by utilizing the earlier reported method of Newbould [ 26 ] . Normally fed male albino rats weighing between 150 and 230 g were used for the experiment. On day 1, 0.1 ml of heat-killed Mycobacterium tuberculosis (Freund's adjuvant complete) was injected into the left hind footpad of each rat. The rats were kept in cages for 15 days. On day 15, all animals with 'developed' arthritis were used for the study and were divided into 6 groups of 6 rats each for various treatments as shown in • ▶ Table 4 . Control group received 1 ml of 0.5 % sodium CMC, standard group received 13.5 mg/kg b.w. of diclofenac. Test groups received 200 mg/kg b.w. of selected compounds 4c, d, h and i . All compounds were administered orally from day 16 to 19. The hind paw volumes, 
Ulcerogenic activity [ 27 ]
Albino rats of either sex were divided into control, standard and different test groups of 6 animals each group (170-250 g). They were starved for 48 h (water ad libitum) prior to drug administration. Control group received only 0.5 % sodium CMC solution, standard group was orally administered with acetylsalicylic acid in sodium CMC solution and test compounds 4c, d, h and i were administered orally at the dose of 200 mg/kg b.w. All animals were sacrifi ced after 7 h of drug administration. Stomach was removed and placed on saline-soaked fi lter paper until inspection. A longitudinal incision along the greater curvature was made with fi ne scissors. The stomach was everted over the index fi nger and the presence or absence of gastric irritationwas determined. The ulcer index for each group was determined according to a previously reported method [36] by counting the number of lesions (x) in each of 5 size classes (y). The classes were defi ned as y = 1 (pinpoint lesion), y = 2 (lesions < 1 mm diameter), y = 3 (lesions 1-2 mm diameter), y = 4 (lesions 2-4 mm diameter) and y = 5 (lesions > 4 mm diameter). The ulcer index was calculated using ∑5 i = 1 x i y i
Antioxidant Activity
Free radical scavenging activity of compounds was determined using 1,1-diphenyl-2-picryl hydrazyl (DPPH) free radical [ 28 ] .
Briefl y, 2 mL samples of various concentrations (100-1 000 μg/ ml) were added to 2 mL of 100 μM DPPH solution. After 20 min incubation at room temperature, the absorbance was read against a blank at 517 nm. The change in absorbance with respect to the control (containing DPPH only without sample, expressed as 100 % free radicals) was calculated as percentage scavenging using following the equation:
(A 517 blank − A 517 sample) ÷ A 517 blank × 100 %.
The reading was taken in triplicate and mean used for calculation of IC 50 . The IC 50 (mean ± SEM) stand for the concentration required for 50 % inhibition of DPPH radicals and was calculated from ORIGIN PC version 6.0 software.
Statistical analysis
Data are presented as arithmetic mean ± SEM. Statistical analysis was performed by one way variance (ANOVA) followed by Dunnett's test,"p" value of less than 0.05 was considered as statistically signifi cant using GRAPHPAD PRISM PC version 4.03 by GraphPad software INC-2005.
Results and Discussion
▼
Synthesis
The synthesis of 3-[3-(substituted phenyl)-1-phenyl-1 H -pyrazol-5-yl]-2 H -chromen-2-one ( 4a-k ) was carried out as pre- Fig. 1 . Starting material 3-acetyl-2 H -chromen-2-one 1 was synthesized by the reaction of salicylaldehyde with ethylacetoacetate in the presence of a catalytic amount of piperidine at room temperature following the literature procedure [ 22 ] .
were synthesized by Claisen-Schmidt condensation of 3-acetyl-2 H -chromen-2-one 1 with various substituted benzaldehydes in the presence of a mixture of piperidine and n-butanol. Eff orts to convert compounds 2a-k into target molecules 4a-k under a variety of conditions were not successful. Hence, an alternative method was adopted. This involved the bromination of chalcones 2a-k and subsequent ring closure using phenyl hydrazine. Bromination of chalcones 2a-k was carried out in chloroform using bromine in chloroform to yield dibromo compounds 3a-k, which were cyclized with phenyl hydrazine in the presence of triethylamine in absolute ethanol to aff ord the 3-[3-(substituted phenyl)-1-phenyl-1 Hpyrazol-5-yl]-2 H -chromen-2-one 4a-k . The physicochemical and spectral analysis data of the synthesized compounds are depicted in • ▶ Table 1 , 2 , respectively.
Acute toxicity study
From the preliminary toxicity studies, it was observed that, all the test compounds have revealed good safety profi le till the uppermost dose (2 000 mg/kg). No mortality of animals observed even after 24 h but there were few changes in the behavioral response like alertness, touch response and restlessness. Therefore, 1/10 th of the maximum tolerated dose i. e., 200 mg/kg b.w.
was chosen for the various pharmacological evaluations.
Acute anti-infl ammatory activity • ▶ Table 3 reveals the in vivo acute anti-infl ammatory activity of a novel series of 3-[3-(substituted phenyl)-1-phenyl-1 H -pyrazol-5-yl]-2 H -chromen-2-one ( 4a-k ) at a dose of 200 mg/kg in carrageenan-induced paw edema method. Carrageenan-induced edema is a non-specifi c infl ammation resulting from a complex of diverse mediators. Since edema of this type is highly sensitive to NSAIDs, carrageenan has been accepted as a useful agent for studying new anti-infl ammatory agents. This model reliably predicts the anti-infl ammatory effi cacy of the NSAIDs, and during the second phase it detects compounds that are anti-infl ammatory agents as a result of inhibition of prostaglandin amplifi cation [35] . As shown in • ▶ Table 3 , the entire investigated Table 4 In vivo chronic anti-infl ammatory activity of selected compounds in adjuvant induced arthritis model. Table 3 In vivo acute anti-infl ammatory activity of 3- 
Ulcerogenic activity
The major drawback of NSAIDs is their gastric ulcer formation due to gastric irritation. The extent of ulcerogenic eff ect was evaluated for compounds 4c, d, h and i in rat stress model at the therapeutic dose (i. e., 200 mg/kg b.w.). The gastric ulcerogenic potential was evaluated by calculating the ulcer index in treated and control animals. Results are given in • ▶ Table 5 that indicates these four compounds (ulcer index ranges from 1.8 to 4.6) cause less gastric ulceration and disruption of gastric epithelial cells at the abovementioned oral dose as compared to acetylsalicylic acid (ulcer index 5.1). Hence gastric tolerance to these compounds was better than that of standard drug.
Antioxidant activity
It has been reported that scavenging of ROS might be benefi cial in reducing the development of infl ammation. In order to determine the extent of scavenging eff ect, all compounds were tested for antioxidant activity using 1,1-diphenyl-2-picryl hydrazyl (DPPH) free radical. All compounds showed antioxidant activity ( • ▶ Table 6 ).
Compounds 4d and k showed 1.03 ± 0.067 and 1.07 ± 0.088 IC 50 as compared with standard ascorbic acid (0.026 ± 0.022 mM) and butylated hydroxy toluene (0.13 ± 0.012 mM). Table 6 Antioxidant activity of 3-[3-(substituted phenyl)-1-phenyl-1 Hpyrazol-5-yl]-2 H -chromen-2-one derivatives ( 4a-k ).
